 Connection
Elizabeth Bayliss to Deprescriptions
This is a "connection" page, showing publications Elizabeth Bayliss has written about Deprescriptions.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
7.811 |
|
|
|
-
Bayliss EA, Goodrich GK, Barrow JC, Harding B, Ripley CA, Kraus CR, Paolino V, Norton JD, Sheehan OC, Weffald LA, Green AR, Palen TE, Reeve E, Maciejewski ML, Boyd CM. Discontinuation Categories Underlying Gaps in Dispensing for Six Medication Groups. Pharmacoepidemiol Drug Saf. 2025 Apr; 34(4):e70142.
Score: 0.901
-
Dublin S, Albertson-Junkans L, Pham Nguyen TP, Pavon JM, Hastings SN, Maciejewski ML, Willis A, Zepel L, Hennessy S, Albers KB, Mowery D, Clark AG, Thomas S, Steinman MA, Boyd CM, Bayliss EA. Defining key deprescribing measures from electronic health data: A multisite data harmonization project. J Am Geriatr Soc. 2025 Feb; 73(2):399-410.
Score: 0.880
-
Boyd CM, Shetterly SM, Powers JD, Weffald LA, Green AR, Sheehan OC, Reeve E, Drace ML, Norton JD, Maiyani M, Gleason KS, Sawyer JK, Maciejewski ML, Wolff JL, Kraus C, Bayliss EA. Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial. Drugs Aging. 2024 Jan; 41(1):45-54.
Score: 0.820
-
Green AR, Weffald LA, Powers JD, Drace ML, Norton JD, Boyd CM, Bayliss EA. Assessing medication appropriateness as a deprescribing outcome. J Am Geriatr Soc. 2023 12; 71(12):3918-3920.
Score: 0.807
-
Bayliss EA, Albers K, Gleason K, Pieper LE, Boyd CM, Campbell NL, Ensrud KE, Gray SL, Linsky AM, Mangin D, Min L, Rich MW, Steinman MA, Turner J, Vasilevskis EE, Dublin S. Recommendations for outcome measurement for deprescribing intervention studies. J Am Geriatr Soc. 2022 09; 70(9):2487-2497.
Score: 0.741
-
Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, Sawyer JK, Weffald LA, Green AR, Reeve E, Maciejewski ML, Sheehan OC, Wolff JL, Kraus C, Boyd CM. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial. JAMA Intern Med. 2022 05 01; 182(5):534-542.
Score: 0.736
-
Green AR, Boyd CM, Gleason KS, Wright L, Kraus CR, Bedoy R, Sanchez B, Norton J, Sheehan OC, Wolff JL, Reeve E, Maciejewski ML, Weffald LA, Bayliss EA. Perspectives on Deprescribing Communication in Primary Care. J Gen Intern Med. 2021 04; 36(4):1122.
Score: 0.683
-
Green AR, Boyd CM, Gleason KS, Wright L, Kraus CR, Bedoy R, Sanchez B, Norton J, Sheehan OC, Wolff JL, Reeve E, Maciejewski ML, Weffald LA, Bayliss EA. Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: a Qualitative Study. J Gen Intern Med. 2020 12; 35(12):3556-3563.
Score: 0.652
-
Bayliss EA, Powers JD, Weffald LA, Rasmussen JR, Pieper LE, Maiyani M, Norton J, Green AR, Sheehan OC, Boyd CM. Central Nervous System Polypharmacy Among People Living With Dementia. J Am Med Dir Assoc. 2025 Aug; 26(8):105708.
Score: 0.229
-
Green AR, Rosado RQ, Daddato AE, Wec A, Gleason K, McPhail TT, Merrey J, Weffald L, Swarthout M, Feeser S, Boyd CM, Wolff JL, Blinka MD, Bayliss EA, Boxer RS. Aligning Medications With What Matters Most: Conversations Between Pharmacists, People With Dementia, and Care Partners. J Am Geriatr Soc. 2025 Apr; 73(4):1189-1197.
Score: 0.223
-
Li X, Bayliss EA, Brookhart MA, Maciejewski ML. Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events. J Am Geriatr Soc. 2025 Mar; 73(3):697-706.
Score: 0.219
-
Norton JD, Zeng C, Bayliss EA, Shetterly SM, Williams N, Reeve E, Wynia MK, Green AR, Drace ML, Gleason KS, Sheehan OC, Boyd CM. Ethical Aspects of Physician Decision-Making for Deprescribing Among Older Adults With Dementia. JAMA Netw Open. 2023 10 02; 6(10):e2336728.
Score: 0.203
-
Reeve E, Bayliss EA, Shetterly S, Maiyani M, Gleason KS, Norton JD, Sheehan OC, Green AR, Maciejewski ML, Drace M, Sawyer J, Boyd CM. Willingness of older people living with dementia and mild cognitive impairment and their caregivers to have medications deprescribed. Age Ageing. 2023 01 08; 52(1).
Score: 0.193
-
Sheehan OC, Gleason KS, Bayliss EA, Green AR, Drace ML, Norton J, Reeve E, Shetterly SM, Weffald LA, Sawyer JK, Maciejewski ML, Kraus C, Maiyani M, Wolff J, Boyd CM. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial. J Am Geriatr Soc. 2023 03; 71(3):774-784.
Score: 0.192
-
Hung A, Sloan CE, Boyd C, Bayliss EA, Hastings SN, Maciejewski ML. Deprescribing medications: Do out-of-pocket costs have a role? J Am Geriatr Soc. 2022 11; 70(11):3334-3337.
Score: 0.187
-
Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. JAMA Intern Med. 2018 12 01; 178(12):1673-1680.
Score: 0.145
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|